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Conclusion  
Replacing chemoradiation with short-course radiotherapy 
and delayed surgery results in a lower chance on pCR in 
patients with stage III rectal cancer LARC compared to 
neoadjuvant CRT. Novel neoadjuvant treatment 
strategies for LARC patients not fit enough for CRT are 
needed in order to increase their eligibility for 
organsparing treatments. 
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Purpose or Objective  
Long-term prevention of metastatic disease remains a 
challenge for locally advanced rectal cancer patients 
undergoing neoadjuvant chemoradiotherapy (CRT). 
Establishment of robust prognostic factors predictive of 
metastatic progression may allow for better patient 
selection for systemic treatment intensification. 
Circulating tumour specific DNA (ctDNA) based on 
hypermethylation of the NPY gene (meth-ctDNA) has 
previously been proposed as a universal marker of 
colorectal cancer. We hypothesised that meth-ctDNA 
could be a prognostic marker in the neoadjuvant setting 
and examined this in a secondary, explorative analysis of 
a prospective clinical trial. 
Material and Methods  
Serum samples were prospectively collected as part of a 
phase III trial of radiotherapy dose escalation for locally 
advanced rectal cancer. Main trial results have previously 
been reported. In summary, patients with MRI-staged T3-
4N0-2M0 rectal cancer and threatened circumferential 
resection margin received 50.4Gy in 28 fractions with 
concomitant oral UFT and L-leucovorin, plus an additional 
10Gy tumour boost in the experimental arm. Baseline 
serum samples were available for 146 patients (out of 224 
treated on trial). DNA was purified from 2-4 ml serum, 
bisulfite converted and analysed by droplet digital PCR. 
Samples were considered positive for meth-ctDNA if >2 
positive droplets/sample, and fractional abundance of 
meth-ctDNA was calculated.   
Overall survival (OS) and rate of distant metastases were 
compared between meth-ctDNA positive and negative 
patients using log-rank tests. Other prognostic factors 
(clinical T and N stage, age for OS) and treatment arm 
were controlled for in multivariate Cox regression 
analysis. The importance of quantitative load was 
examined by considering the fractional abundance of 
meth-ctDNA. 
Results  
Patient characteristics were representative of the main 
trial population (median age 64 years, 64% male patients, 
19% T4 tumours, 87% N positive). Thirty patients out of 
146 had meth-ctDNA in baseline serum samples, with no 
correlation with clinical T and N stages (p=0.8 and p=0.6, 
respectively). Median follow-up was 10.6 years 
(interquartile range, IQR, 9.2-11.5 years) for OS and 5.1 
years (IQR 3.7-6.0 years) for freedom from distant 
metastases. Patients with meth-ctDNA had significantly 
worse OS at 5 years (47% vs 69%, p=0.02), Figure 1a, even 
when controlling for other prognostic factors (HR=2.08, 
95% CI 1.23-1.51, p=0.007). This difference appeared 
mainly driven by disparity in the rate of distant 
metastases (55% vs 72% at 5 years, p=0.01), Figure 1b, 
with HR=2.20 (1.19-4.07, p=0.01) in multivariate analysis. 
Increased quantitative load was highly significant for 
worse outcomes (p<0.0001 and p=0.001, for OS and 
distant metastases, respectively). 
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Conclusion  
Hypermethylation of circulating tumour specific DNA 
could be a potential prognostic marker in the 
neoadjuvant setting and may, if validated, help identify 
patients at increased risk of distant metastases. 
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Purpose or Objective  
Evaluation of clinical practice, treatment and outcome 
after treatment of anal cancers in the French national 
cohort ANABASE. 
Material and Methods  
This prospective national multicentric observational 
cohort included all patients (pts) treated for an anal 
cancer in 59 French centers from January 2015 to 
September 2017. Pts were treated according to French 
guidelines and local expertise of each center. Pts and 
tumor characteristics, treatments (chemotherapy (CT), 
radiotherapy (RT), and surgery) and outcomes were 
analyzed. Colostomy-free, disease-free and overall 
survivals at 3 years will be studied. Here we presented 
the results at 4-6 months after treatment for patients 
with non-metastatic anal cancer. Univariate and 
multivariate analyses were performed by logistic 
regression in order to determine factors associated with 
complete response at 4-6 months. 
Results  
Among 627 pts with anal cancer 450 were treated for a 
non-metastatic disease. Pts characteristics were as 
follow: median age: 64 years (range 35-94); gender: 106 
males (23.6%) and 344 females (76.4%). Tumors were 
classified as locally limited (T0-1-2, N0, M0) for 183 pts 
(40.8%) and locally advanced (T3-4 or N+, M0) for 266 pts 
(59.2%). Initial staging included a conventional CT-scan 
for 53.4 % of pts, MRI for 65.4%, PET-CT for 59.7% and 
echo-endoscopy for 32.8%. Among 239 pts with complete 
data about RT treatment, IMRT was used for 86.6% versus 
3D for 13.4% of pts. Median total dose was 60 Gy (range 
14-73), 56 pts had a brachytherapy boost. An interruption 
of treatment was made for 48.2% of pts, with a median 
duration of 15 days (range 1-56), because of toxicity in 
34.7% of cases but mostly as planned gap in 61.9 % of 
cases. A concomitant CT was administered for 286 pts, 
including mitomycin-based CT for 82.2%, cisplatin-based 
CT for 9% and 5FU alone for 8.4%. An induction CT before 
RCT was administered for 31 pts (11.8%). Among 266 
patients with an evaluation 4 to 6 months after the end 
of treatment, 67.2 % experienced a complete response, 
whereas 21.8% had a stable disease or a partial response, 
and 10.9 % had a progressive disease. Factors associated 
with complete response at 4–6 months in univariate 
analysis were initial staging (locally limited) (OR=1.85, 
95%CI=1.1-3.2, p=0.027), tumor size <3cm (OR=2.1, 
95%CI=1.1-3.9, p=0.024), whereas induction 
chemotherapy (OR=0.36, 95%CI=0.15-0.86, p=0.022) and 
RT dose (<50 Gy vs ≥60 Gy) OR=0.58, 95%CI=0.29-1.14, 
p=0.023) were associated with absence of complete 
response. In multivariate analysis, no factor was 
associated with complete response at 4-6 months but RT 
dose had a trend towards significance (OR=0.55, 
95%CI=0.25-1.25, p=0.08). 
Conclusion  
First results of the ANABASE cohort showed a good 
accordance with actual guidelines for anal cancer 
treatment with the use of IMRT treatments for 86.6% of 
pts and mitomycin-based chemotherapy for 82.2% of pts. 
However, a systematic treatment gap was still planned 
for 29.8 % of pts.  
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Purpose or Objective  
In high-risk prostate cancer, the risk of occult lymph node 
metastases in the pelvic lymph nodes can be as high as 
40%. However, the use of whole pelvis radiotherapy 
(WPRT) in high-risk patients remains controversial with 
inconsistent results from published clinical studies to 
date. Data from a national UK database of patients 
treated with external-beam radiotherapy (EBRT) and 
high-dose rate (HDR) brachytherapy was reviewed to 
evaluate the benefit of pelvic treatment. 
Material and Methods  
From 2009 to 2013, 755 patients with intermediate- and 
high-risk prostate cancer (clinical stage ≥T2b or Gleason 
score ≥7 or presenting prostate-specific antigen (pPSA) 
≥10) were treated in a UK national protocol with EBRT 
and HDR brachytherapy. Whole pelvis EBRT including the 
pelvic nodes to the level of the common iliac chain was 
given to 370 patients to a dose of 46Gy in 23 fractions 
and radiotherapy to the prostate only (PORT) was given 
to 385 patients to a dose of 37.5Gy in 15 fractions. HDR 
brachytherapy 15Gy single dose was given to all cases. 
Corresponding biologic equivalent prostate doses to 2Gy 
per fraction (EQD2) were 107Gy and 100Gy respectively 
(α/β = 1.5). Brachytherapy planning objectives were 
rectum D2cc <12Gy with a maximum <15Gy and urethra 
D10 <17.5Gy, D30 <16.5Gy and maximum <22.5Gy. ADT 
was given to 96.5% of patients with a median duration of 
24 months. Biochemical failure was defined as a PSA rise 
of ≥2ng/ml above the nadir value after radiotherapy. 
Acute and late genitourinary (GU) and gastrointestinal 
(GI) toxicities were evaluated using the Common 
Terminology Criteria for Adverse Events, version 4.0 
guidelines. Late toxicity was defined as that originating 
≥90 days after completion of radiotherapy. Statistical 
analysis used log-rank and Cox univariate and 
multivariate tests. 
 
